{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T18:11:53Z","timestamp":1770228713422,"version":"3.49.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Zhejiang Provincial Clinical Research Center for Respiratory Disease","award":["2022E50005"],"award-info":[{"award-number":["2022E50005"]}]},{"name":"Key R&D Program of Zhejiang Respiratory Disease","award":["No.2023C03069"],"award-info":[{"award-number":["No.2023C03069"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"DOI":"10.1186\/s12890-025-03570-8","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T11:33:12Z","timestamp":1741865592000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Risk factors of immune-related endocrine toxicities in non-small cell lung cancer patients treated with pembrolizumab and its impact on patient outcomes: a multicenter retrospective study"],"prefix":"10.1186","volume":"25","author":[{"given":"Haoting","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenyi","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenlin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuping","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianya","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"issue":"3","key":"3570_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"3570_CR2","first-page":"217","volume":"24","author":"C Zhou","year":"2021","unstructured":"Zhou C, Wang J, Wang B, Cheng Y, Wang Z, Han B, Lu Y, Wu G, Zhang L, Song Y, et al. [Chinese experts consensus on immune checkpoint inhibitors for Non-small cell lung Cancer (2020 Version)]. Zhongguo Fei Ai Za Zhi. 2021;24(4):217\u201335.","journal-title":"Zhongguo Fei Ai Za Zhi"},{"issue":"11","key":"3570_CR3","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1080\/21645515.2016.1199310","volume":"12","author":"G Kwok","year":"2016","unstructured":"Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL. Pembrolizumab (Keytruda). Hum Vaccin Immunother. 2016;12(11):2777\u201389.","journal-title":"Hum Vaccin Immunother"},{"issue":"10027","key":"3570_CR4","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW, Felip E, P\u00e9rez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540\u201350.","journal-title":"Lancet"},{"issue":"19","key":"3570_CR5","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al. Pembrolizumab versus chemotherapy for PD-L1-Positive Non-Small-Cell lung Cancer. N Engl J Med. 2016;375(19):1823\u201333.","journal-title":"N Engl J Med"},{"issue":"10183","key":"3570_CR6","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr., Srimuninnimit V, Laktionov KK, Bondarenko I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819\u201330.","journal-title":"Lancet"},{"issue":"11","key":"3570_CR7","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","volume":"17","author":"CJ Langer","year":"2016","unstructured":"Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17(11):1497\u2013508.","journal-title":"Lancet Oncol"},{"issue":"22","key":"3570_CR8","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, et al. Pembrolizumab plus chemotherapy in metastatic Non-Small-Cell lung Cancer. N Engl J Med. 2018;378(22):2078\u201392.","journal-title":"N Engl J Med"},{"issue":"21","key":"3570_CR9","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares L, Luft A, Vicente D, Tafreshi A, G\u00fcm\u00fc\u015f M, Mazi\u00e8res J, Hermes B, \u00c7ay \u015eenler F, Cs\u0151szi T, F\u00fcl\u00f6p A, et al. Pembrolizumab plus chemotherapy for squamous Non-Small-Cell lung Cancer. N Engl J Med. 2018;379(21):2040\u201351.","journal-title":"N Engl J Med"},{"issue":"5","key":"3570_CR10","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.ando.2018.07.008","volume":"79","author":"C Briet","year":"2018","unstructured":"Briet C, Albarel F, Kuhn E, Merlen E, Chanson P, Cortet C. Expert opinion on pituitary complications in immunotherapy. Ann Endocrinol (Paris). 2018;79(5):562\u20138.","journal-title":"Ann Endocrinol (Paris)"},{"issue":"8","key":"3570_CR11","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.2337\/dbi18-0002","volume":"67","author":"AM Stamatouli","year":"2018","unstructured":"Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, Gettinger S, Sznol M, Young A, Rushakoff R, et al. Collateral damage: Insulin-Dependent diabetes induced with checkpoint inhibitors. Diabetes. 2018;67(8):1471\u201380.","journal-title":"Diabetes"},{"issue":"2","key":"3570_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.tem.2021.10.009","volume":"33","author":"S Chiloiro","year":"2022","unstructured":"Chiloiro S, Bianchi A, Giampietro A, Milardi D, De Marinis L, Pontecorvi A. The changing clinical spectrum of endocrine adverse events in cancer immunotherapy. Trends Endocrinol Metab. 2022;33(2):87\u2013104.","journal-title":"Trends Endocrinol Metab"},{"issue":"11","key":"3570_CR13","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1111\/cas.13800","volume":"109","author":"S Kimbara","year":"2018","unstructured":"Kimbara S, Fujiwara Y, Iwama S, Ohashi K, Kuchiba A, Arima H, Yamazaki N, Kitano S, Yamamoto N, Ohe Y. Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab. Cancer Sci. 2018;109(11):3583\u201390.","journal-title":"Cancer Sci"},{"issue":"4","key":"3570_CR14","doi-asserted-by":"publisher","first-page":"e199","DOI":"10.1016\/j.lpm.2018.10.019","volume":"48","author":"P Campredon","year":"2019","unstructured":"Campredon P, Mouly C, Lusque A, Bigay-Game L, Bousquet E, Mazi\u00e8res J, Caron P. Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: retrospective study of 105 patients. Presse Med. 2019;48(4):e199\u2013207.","journal-title":"Presse Med"},{"key":"3570_CR15","doi-asserted-by":"crossref","unstructured":"Pollack R, Ashash A, Cahn A, Rottenberg Y, Stern H, Dresner-Pollak R. Immune checkpoint Inhibitor-induced thyroid dysfunction is associated with higher body mass index. J Clin Endocrinol Metab 2020, 105(10).","DOI":"10.1210\/clinem\/dgaa458"},{"issue":"3","key":"3570_CR16","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2217\/imt-2020-0179","volume":"13","author":"FG Dall\u2019Olio","year":"2021","unstructured":"Dall\u2019Olio FG, Rizzo A, Mollica V, Massucci M, Maggio I, Massari F. Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: a meta-analysis. Immunotherapy. 2021;13(3):257\u201370.","journal-title":"Immunotherapy"},{"key":"3570_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.lungcan.2019.05.029","volume":"134","author":"U Dafni","year":"2019","unstructured":"Dafni U, Tsourti Z, Vervita K, Peters S. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis. Lung Cancer. 2019;134:127\u201340.","journal-title":"Lung Cancer"},{"issue":"3","key":"3570_CR18","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1055\/a-0843-3366","volume":"51","author":"J de Filette","year":"2019","unstructured":"de Filette J, Andreescu CE, Cools F, Bravenboer B, Velkeniers B. A systematic review and Meta-Analysis of Endocrine-Related adverse events associated with immune checkpoint inhibitors. Horm Metab Res. 2019;51(3):145\u201356.","journal-title":"Horm Metab Res"},{"issue":"2","key":"3570_CR19","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","volume":"4","author":"R Barroso-Sousa","year":"2018","unstructured":"Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, Tolaney SM. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: A systematic review and Meta-analysis. JAMA Oncol. 2018;4(2):173\u201382.","journal-title":"JAMA Oncol"},{"issue":"21","key":"3570_CR20","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1200\/JCO.20.03579","volume":"39","author":"M Boyer","year":"2021","unstructured":"Boyer M, \u015eendur MAN, Rodr\u00edguez-Abreu D, Park K, Lee DH, \u00c7i\u00e7in I, Yumuk PF, Orlandi FJ, Leal TA, Molinier O, et al. Pembrolizumab plus ipilimumab or placebo for metastatic Non-Small-Cell lung Cancer with PD-L1 tumor proportion score\u2009\u2265\u200950%: randomized, Double-Blind phase III KEYNOTE-598 study. J Clin Oncol. 2021;39(21):2327\u201338.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3570_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12902-022-01004-8","volume":"22","author":"HS Baek","year":"2022","unstructured":"Baek HS, Jeong C, Shin K, Lee J, Suh H, Lim DJ, Kang MI, Ha J. Association between the type of thyroid dysfunction induced by immune checkpoint inhibitors and prognosis in cancer patients. BMC Endocr Disord. 2022;22(1):89.","journal-title":"BMC Endocr Disord"},{"issue":"5","key":"3570_CR22","doi-asserted-by":"publisher","first-page":"e0216954","DOI":"10.1371\/journal.pone.0216954","volume":"14","author":"I Yamauchi","year":"2019","unstructured":"Yamauchi I, Yasoda A, Matsumoto S, Sakamori Y, Kim YH, Nomura M, Otsuka A, Yamasaki T, Saito R, Kitamura M, et al. Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab. PLoS ONE. 2019;14(5):e0216954.","journal-title":"PLoS ONE"},{"issue":"1","key":"3570_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s12020-023-03323-9","volume":"81","author":"L Wu","year":"2023","unstructured":"Wu L, Xu Y, Wang X, Cheng X, Zhang Y, Wang Y, Fan X, Zhao H, Liu H, Chai X, et al. Thyroid dysfunction after immune checkpoint inhibitor treatment in a single-center Chinese cohort: a retrospective study. Endocrine. 2023;81(1):123\u201333.","journal-title":"Endocrine"},{"issue":"10","key":"3570_CR24","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1089\/thy.2020.0032","volume":"30","author":"CA Muir","year":"2020","unstructured":"Muir CA, Menzies AM, Clifton-Bligh R, Tsang VHM. Thyroid toxicity following immune checkpoint inhibitor treatment in advanced Cancer. Thyroid. 2020;30(10):1458\u201369.","journal-title":"Thyroid"},{"issue":"17","key":"3570_CR25","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al. Nivolumab versus docetaxel in advanced nonsquamous Non-Small-Cell lung Cancer. N Engl J Med. 2015;373(17):1627\u201339.","journal-title":"N Engl J Med"},{"issue":"2","key":"3570_CR26","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, Crin\u00f2 L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al. Nivolumab versus docetaxel in advanced Squamous-Cell Non-Small-Cell lung Cancer. N Engl J Med. 2015;373(2):123\u201335.","journal-title":"N Engl J Med"},{"issue":"10","key":"3570_CR27","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1089\/thy.2018.0116","volume":"28","author":"PC Iyer","year":"2018","unstructured":"Iyer PC, Cabanillas ME, Waguespack SG, Hu MI, Thosani S, Lavis VR, Busaidy NL, Subudhi SK, Diab A, Dadu R. Immune-Related thyroiditis with immune checkpoint inhibitors. Thyroid. 2018;28(10):1243\u201351.","journal-title":"Thyroid"},{"issue":"12","key":"3570_CR28","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1158\/2326-6066.CIR-17-0208","volume":"5","author":"H Lee","year":"2017","unstructured":"Lee H, Hodi FS, Giobbie-Hurder A, Ott PA, Buchbinder EI, Haq R, Tolaney S, Barroso-Sousa R, Zhang K, Donahue H, et al. Characterization of thyroid disorders in patients receiving immune checkpoint Inhibition therapy. Cancer Immunol Res. 2017;5(12):1133\u201340.","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"3570_CR29","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/annonc\/mdw640","volume":"28","author":"JC Osorio","year":"2017","unstructured":"Osorio JC, Ni A, Chaft JE, Pollina R, Kasler MK, Stephens D, Rodriguez C, Cambridge L, Rizvi H, Wolchok JD, et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint Blockade in patients with non-small-cell lung cancer. Ann Oncol. 2017;28(3):583\u20139.","journal-title":"Ann Oncol"},{"issue":"6","key":"3570_CR30","first-page":"1225","volume":"31","author":"H Yamazaki","year":"2017","unstructured":"Yamazaki H, Iwasaki H, Yamashita T, Yoshida T, Suganuma N, Yamanaka T, Masudo K, Nakayama H, Kohagura K, Rino Y, Masuda M. Potential risk factors for Nivolumab-induced thyroid dysfunction. Vivo. 2017;31(6):1225\u20138.","journal-title":"Vivo"},{"key":"3570_CR31","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.lungcan.2021.08.009","volume":"161","author":"N Zhou","year":"2021","unstructured":"Zhou N, Velez MA, Bachrach B, Gukasyan J, Fares CM, Cummings AL, Lind-Lebuffe JP, Akingbemi WO, Li DY, Brodrick PM, et al. Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC. Lung Cancer. 2021;161:34\u201341.","journal-title":"Lung Cancer"},{"issue":"9","key":"3570_CR32","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1002\/ijc.33399","volume":"148","author":"YL Wu","year":"2021","unstructured":"Wu YL, Zhang L, Fan Y, Zhou J, Zhang L, Zhou Q, Li W, Hu C, Chen G, Zhang X, et al. Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China study. Int J Cancer. 2021;148(9):2313\u201320.","journal-title":"Int J Cancer"},{"issue":"9","key":"3570_CR33","doi-asserted-by":"publisher","first-page":"e3704","DOI":"10.1210\/clinem\/dgab263","volume":"106","author":"CA Muir","year":"2021","unstructured":"Muir CA, Clifton-Bligh RJ, Long GV, Scolyer RA, Lo SN, Carlino MS, Tsang VHM, Menzies AM. Thyroid immune-related adverse events following immune checkpoint inhibitor treatment. J Clin Endocrinol Metab. 2021;106(9):e3704\u201313.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"3570_CR34","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1634\/theoncologist.2018-0563","volume":"24","author":"A Pavan","year":"2019","unstructured":"Pavan A, Calvetti L, Dal Maso A, Attili I, Del Bianco P, Pasello G, Guarneri V, Aprile G, Conte P, Bonanno L. Peripheral blood markers identify risk of Immune-Related toxicity in advanced Non-Small cell lung Cancer treated with Immune-Checkpoint inhibitors. Oncologist. 2019;24(8):1128\u201336.","journal-title":"Oncologist"},{"issue":"9","key":"3570_CR35","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1007\/s00262-020-02585-w","volume":"69","author":"L Peng","year":"2020","unstructured":"Peng L, Wang Y, Liu F, Qiu X, Zhang X, Fang C, Qian X, Li Y. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors. Cancer Immunol Immunother. 2020;69(9):1813\u201322.","journal-title":"Cancer Immunol Immunother"},{"issue":"10","key":"3570_CR36","doi-asserted-by":"publisher","first-page":"e4115","DOI":"10.1210\/clinem\/dgac467","volume":"107","author":"T Kobayashi","year":"2022","unstructured":"Kobayashi T, Iwama S, Yamagami A, Yasuda Y, Okuji T, Ito M, Zhou X, Ando M, Onoue T, Miyata T, et al. Elevated TSH level, TgAb, and prior use of ramucirumab or TKIs as risk factors for thyroid dysfunction in PD-L1 Blockade. J Clin Endocrinol Metab. 2022;107(10):e4115\u201323.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"3570_CR37","doi-asserted-by":"publisher","first-page":"824","DOI":"10.4158\/EP-2018-0472","volume":"25","author":"RM Pollack","year":"2019","unstructured":"Pollack RM, Kagan M, Lotem M, Dresner-Pollak R. BASELINE TSH LEVEL IS ASSOCIATED WITH RISK OF ANTI-PD-1-INDUCED THYROID DYSFUNCTION. Endocr Pract. 2019;25(8):824\u20139.","journal-title":"Endocr Pract"},{"issue":"10","key":"3570_CR38","doi-asserted-by":"publisher","first-page":"e1056","DOI":"10.1210\/clinem\/dgad231","volume":"108","author":"X Zhou","year":"2023","unstructured":"Zhou X, Iwama S, Kobayashi T, Ando M, Arima H. Risk of thyroid dysfunction in PD-1 Blockade is stratified by the pattern of TgAb and TPOAb positivity at baseline. J Clin Endocrinol Metab. 2023;108(10):e1056\u201362.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"3570_CR39","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1089\/thy.2017.0062","volume":"27","author":"K Torimoto","year":"2017","unstructured":"Torimoto K, Okada Y, Nakayamada S, Kubo S, Tanaka Y. Anti-PD-1 antibody therapy induces Hashimoto\u2019s disease with an increase in peripheral blood follicular helper T cells. Thyroid. 2017;27(10):1335\u20136.","journal-title":"Thyroid"},{"issue":"12","key":"3570_CR40","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1007\/s40618-019-01058-x","volume":"42","author":"I Mazarico","year":"2019","unstructured":"Mazarico I, Capel I, Gim\u00e9nez-Palop O, Albert L, Berges I, Luchtenberg F, Garc\u00eda Y, Fern\u00e1ndez-Morales LA, De Pedro VJ, Caix\u00e0s A, Rigla M. Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors. J Endocrinol Invest. 2019;42(12):1443\u201350.","journal-title":"J Endocrinol Invest"},{"issue":"7","key":"3570_CR41","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1089\/thy.2016.0562","volume":"27","author":"I Yamauchi","year":"2017","unstructured":"Yamauchi I, Sakane Y, Fukuda Y, Fujii T, Taura D, Hirata M, Hirota K, Ueda Y, Kanai Y, Yamashita Y, et al. Clinical features of Nivolumab-Induced thyroiditis: A case series study. Thyroid. 2017;27(7):894\u2013901.","journal-title":"Thyroid"},{"issue":"2","key":"3570_CR42","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3803\/EnM.2020.906","volume":"36","author":"JH Yoon","year":"2021","unstructured":"Yoon JH, Hong AR, Kim HK, Kang HC. Characteristics of Immune-Related thyroid adverse events in patients treated with PD-1\/PD-L1 inhibitors. Endocrinol Metab (Seoul). 2021;36(2):413\u201323.","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"1","key":"3570_CR43","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s12020-019-01854-8","volume":"69","author":"S Gay","year":"2020","unstructured":"Gay S, Rossi G, Corica G, Graziani G, Genova C, Rijavec E, Tagliamento M, Grossi F, Giusti M. RETRACTED ARTICLE: can baseline endocrinological examination and thyroid ultrasound predict the development of thyroid disease in immunotherapy-treated patients? Results from a prospective, single-center, open-label study. Endocrine. 2020;69(1):233.","journal-title":"Endocrine"},{"issue":"1","key":"3570_CR44","doi-asserted-by":"publisher","first-page":"e1375642","DOI":"10.1080\/2162402X.2017.1375642","volume":"7","author":"HI Kim","year":"2017","unstructured":"Kim HI, Kim M, Lee SH, Park SY, Kim YN, Kim H, Jeon MJ, Kim TY, Kim SW, Kim WB, et al. Development of thyroid dysfunction is associated with clinical response to PD-1 Blockade treatment in patients with advanced non-small cell lung cancer. Oncoimmunology. 2017;7(1):e1375642.","journal-title":"Oncoimmunology"},{"issue":"7","key":"3570_CR45","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1007\/s00262-020-02802-6","volume":"70","author":"P Thuillier","year":"2021","unstructured":"Thuillier P, Joly C, Alavi Z, Crouzeix G, Descourt R, Quere G, Kerlan V, Roudaut N. Thyroid dysfunction induced by immune checkpoint inhibitors is associated with a better progression-free survival and overall survival in non-small cell lung cancer: an original cohort study. Cancer Immunol Immunother. 2021;70(7):2023\u201333.","journal-title":"Cancer Immunol Immunother"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-025-03570-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-025-03570-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-025-03570-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T11:55:16Z","timestamp":1741866916000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-025-03570-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3570"],"URL":"https:\/\/doi.org\/10.1186\/s12890-025-03570-8","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,13]]},"assertion":[{"value":"29 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experiments were performed in accordance with relevant guidelines and regulations (such as the Declaration of Helsinki). This study was reviewed and approved by the Ethical Committee of the First Affiliated Hospital, College of Medicine, Zhejiang University on October 24th (Number: 2019\u2009\u2212\u20091433) and by the Ethical Committee of the Fourth Affiliated Hospital, College of Medicine, Zhejiang University on November 13th (Number: 20231108). Given the retrospective nature of this study, informed consent exemption was obtained for this study from Ethics Committee of the First Affiliated Hospital of Zhejiang University, the Fourth Affiliated Hospital of Zhejiang University, Guangfu Hospital, Affiliated Hospital of Jiaxing University and the First Affiliated Hospital Wenzhou Medical College.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"111"}}